Home The Action Management Committee Dr. Päivi Lakkisto (FI)

Thu,23Feb2017

Dr. Päivi Lakkisto

Senior Researcher and Senior Lecturer
Minerva Institute for Medical Research
Unit of Cardiovascular Research
Biomedicum Helsinki 2
Tukholmankatu 8
FI-00290 Helsinki
Finland

University of Helsinki
Department of Clinical Chemistry
Biomedicum Helsinki
Haartmaninkatu 8
FI-00290 Helsinki
Finland

T: +358 9 191 25702
F: +358 9 191 2570
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Interests

  • Molecular mechanisms of heart failure
  • Myocardial repair and regeneration
  • Role of HO-1 and CO in cardiac diseases

Selected Recent Publications

  •  Lakkisto P, Kytö V, Forsten H, Siren J-M, Segersvärd H, Voipio-Pulkki L-M, Laine M, Pulkki K, Tikkanen I. Heme oxygenase-1 and carbon monoxide promote neovascularization after myocardial infarction by modulating the expression of HIF-1alpha, SDF-1alpha and VEGF-B. Eur J Pharmacol 2010;635:156-164.
  • Saukkonen K, Lakkisto P, Kaunisto M, Varpula M, Voipio-Pulkki L-M, Varpula T, Pettilä V, Pulkki K. Heme oxygenase-1 polymorphism and plasma concentrations in the critically ill patients. Shock. 2010;34:558-564.
  • Siltanen A, Kitabayashi K, Lakkisto P, Mäkelä J, Pätilä T, Ono M, Tikkanen I, Sawa Y, Kankuri E, Harjula A. hHGF overexpression in myoblast sheets enhances their angiogenic potential in rat chronic heart failure. PLoS One. 2011;6:e19161.
  • Lakkisto P, Siren J-M, Kytö V, Forsten H, Laine M, Pulkki K, Tikkanen I. Heme oxygenase-1 induction protects the heart and modulates cellular and extracellular remodelling after myocardial infarction in rats. Exp Biol Med 2011;236:1437-1448.
  • Segersvärd H, Lakkisto P, Forsten H, Immonen K, Kosonen R, Palojoki E, Kankuri E, Harjula A, Laine M, Tikkanen I. Effects of angiotensin II blockade on cardiomyocyte regeneration after myocardial infarction in rats. J Renin Angiotensin Aldosterone Syst. 2013 Apr 29. [Epub ahead of print]

ESF

COST

POLICY STATEMENT: Biomedicine and Molecular Biosciences Action BM1005 is funded by COST, through its implementing agent the European Science Foundation.